Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Irinotecan With TAS102 and Bevacizumab for Metastatic Colorectal Cancer
NCT05854498Phase 2Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Oct 2023
- Primary completion
- Sep 2028
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nanoliposomal irinotecan in colorectal cancer (CRC), sponsored by University of Wisconsin–Madison. Started Oct 2023; status: recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05854498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05854498.